Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.

Pediatric blood & cancer - 1 Jun 2021

Jain Payal, Surrey Lea F, Straka Joshua, Russo Pierre, Womer Richard, Li Marilyn M, Storm Phillip B, Waanders Angela J, Hogarty Michael D, Resnick Adam C, Picarsic Jennifer

Abstract excerpt

Pediatric histiocytic neoplasms are hematopoietic disorders frequently driven by the BRAF-V600E mutation. Here, we identified two BRAF gene fusions (novel MTAP-BRAF and MS4A6A-BRAF) in two aggressive histiocytic neoplasms. In contrast to previously described BRAF fusions, MTAP-BRAF and MS4A6A-BRAF do not respond to the paradox breaker RAF inhibitor (RAFi) PLX8394 due to stable fusion dimerization mediated by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 33565241
DOI: 10.1002/pbc.28933

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.PMID 33565241Read ↗

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersSemantic proximity Read ↗

Novel BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersSemantic proximity Read ↗

Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.Semantic proximity Read ↗

CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profilesSemantic proximity Read ↗

Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.Semantic proximity Read ↗

BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.Semantic proximity Read ↗

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathwaysSemantic proximity Read ↗

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.Semantic proximity Read ↗

A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.Semantic proximity Read ↗

Targeting BRAF in pediatric brain tumors.Semantic proximity Read ↗

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytomaSemantic proximity Read ↗

Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.